Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Leukemia"
DOI: 10.1038/s41375-025-02518-5
Abstract: BCMA-targeted CAR T-cells transformed the treatment of relapsed and refractory multiple myeloma (RRMM), yet improvements are needed in manufacturing, toxicity and efficacy. We conducted a phase 1 clinical trial of BMS-986354, an autologous BCMA CAR… read more here.
Keywords: antigen; triple class; car; cell ... See more keywords
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01135-2
Abstract: Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line treatment. Effective treatment for this… read more here.
Keywords: exposed refractory; multiple myeloma; subgroup analysis; analysis ... See more keywords
Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2023.2154648
Abstract: ABSTRACT Objectives Although multiple myeloma (MM) survival has improved following the introduction of proteosome inhibitors, immunomodulatory drugs, and anti-CD38 therapies, patients become refractory to these agents. Real-world outcomes of triple-class exposed patients are limited and… read more here.
Keywords: exposure; outcomes triple; triple class; class ... See more keywords
How I treat triple-class refractory multiple myeloma.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of haematology"
DOI: 10.1111/bjh.18185
Abstract: Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti-CD38 monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM) therapy. The prognosis of patients with MM that became refractory to these three classes (triple-class… read more here.
Keywords: multiple myeloma; triple class; class refractory;
Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2021 at "European journal of haematology"
DOI: 10.1111/ejh.13697
Abstract: BACKGROUND Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple-class relapsed/refractory MM (RRMM). Descriptive analyses were performed on available data for patient characteristics, disease course, and outcomes of… read more here.
Keywords: relapsed refractory; class; triple class; multiple myeloma ... See more keywords
Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5815
Abstract: Introduction: Teclistamab (tec) is the first globally approved B-cell maturation antigen (BCMA) × CD3 bispecific antibody (BsAb) with weight-based dosing. Tec demonstrated deep, and durable responses with a manageable safety profile in patients with triple-class… read more here.
Keywords: cohort; trial; response; non trial ... See more keywords
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2022-0045
Abstract: Aim: To compare the efficacy of idecabtagene vicleucel (ide-cel, bb2121) versus conventional care (CC) in triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Patients & methods: A matching-adjusted indirect comparison was conducted using individual… read more here.
Keywords: care triple; versus conventional; idecabtagene vicleucel; triple class ... See more keywords
Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0846
Abstract: Aim: Treatment options for triple-class exposed (TCE) patients with multiple myeloma (MM) in Japan are limited. Materials & methods: Retrospective observational study using the Medical Data Vision database (April 2008-April 2021). Eligible adults with MM… read more here.
Keywords: triple class; myeloma japan; class exposed; treatment ... See more keywords
Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29070355
Abstract: Major progress has been made in the upfront treatment of multiple myeloma, but the disease ultimately relapses and leads to death in the vast majority of those afflicted. New treatment strategies and modalities are necessary… read more here.
Keywords: refractory; triple class; myeloma; treatment ... See more keywords
Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Comparative Effectiveness Research"
DOI: 10.57264/cer-2024-0236
Abstract: Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiple myeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matching-adjusted indirect comparison (MAIC) of the… read more here.
Keywords: exposed refractory; treatment; patients triple; triple class ... See more keywords